Liposarcoma is a malignancy of fat cells. In adults, it is the most common soft tissue sarcoma. Liposarcoma normally appears as a slowly enlarging, painless, nonulcerated submucosal mass in a middle-aged person, but some lesions grow rapidly and become ulcerated early. Liposarcoma is a lipogenic tumor of large deep-seated connective tissue spaces. Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. An abnormality of band 12q13 has been associated with the development of liposarcomas. The most common chromosomal translocation is the FUS-CHOP fusion gene, which encodes a transcription factor necessary for adipocyte differentiation.
These and other distinct genetic aberrations may aid in the diagnosis of particular liposarcoma subtypes, and they can potentially be targets that can be exploited therapeutically. The symptoms includes Chest pain, Trouble swallowing or weight loss, Trouble urinating or pain while urinating, Pain and swelling in the area of your tumor, Coughing or trouble speaking and breathing, Decreased movement in the limb that has the tumor. Treatment including Surgery, Radiation, Chemotherapy.
Soft tissue sarcoma accounts for <1% of all malignant tumors in adults, with an estimated incidence of 4–5/100,000/year in Europe. About 10–15% of adult STS are located in the RP. Liposarcoma is the most common variant and accounts for 20% of all STS, and over 50% of RP sarcomas.